247193-36-8

Basic information

• Product Name: 2-Iodo-9-methyl-9H-purine
• Synonyms: 2-Iodo-9-methyl-9H-purine;6-CHLORO-2-IODO-9-METHYL-9H-PURINE
• CAS NO: 247193-36-8
• Molecular Formula: C₆H₄ClIN₄
• Molecular Weight: 260.03517
• Mol File: 247193-36-8.mol

Chemical Properties

• Boiling Point: 450.3±55.0 °C(Predicted)
• Appearance: /
• Density: 2.39±0.1 g/cm3(Predicted)
• PKA: -0.73±0.10(Predicted)
• CAS DataBase Reference: 2-Iodo-9-methyl-9H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Iodo-9-methyl-9H-purine(247193-36-8)
• EPA Substance Registry System: 2-Iodo-9-methyl-9H-purine(247193-36-8)

Safety Data

• Hazardous Substances Data: 247193-36-8(Hazardous Substances Data)

Upstream product

• 3035-73-2 6-chloro-9-methyl-9H-2-purinylamine 
• 327161-48-8 N₁-(6-chloro-9-methyl-9H-2-purinyl)acetamide 
• 327161-45-5 N₁-[5-amino-4-chloro-6-(methylamino)-2-pyrimidinyl]acetamide 
• 232254-95-4 N₁-[4-chloro-6-(methylamino)-5-nitro-2-pyrimidinyl]acetamide 
• 330433-43-7 6-chloro-N⁴-methyl-pyrimidine-2,4,5-triamine 
• 18552-90-4 6-chloro-2-iodo-(9H)-purine 
• 74-88-4 methyl iodide 

Downstream Products

• 327161-49-9 1-[2-(6-chloro-9-methyl-9H-2-purinyl)-1-ethynyl]-1-cyclohexanol 
• 552315-12-5 (2-chloro-phenyl)-(2-iodo-9-methyl-9H-purin-6-yl)-amine 
• 672958-39-3 (2,6-difluoro-phenyl)-(9-methyl-2-phenyl-9H-purin-6-yl)-amine 
• 672958-45-1 (2,6-difluoro-phenyl)-(9-methyl-2-o-tolyl-9H-purin-6-yl)-amine 
• 672958-40-6 (2,6-difluoro-phenyl)-(9-methyl-2-m-tolyl-9H-purin-6-yl)-amine 
• 672958-41-7 (2,6-difluoro-phenyl)-(9-methyl-2-p-tolyl-9H-purin-6-yl)-amine 
• 552315-13-6 (2-chloro-phenyl)-[2-(4-fluoro-2-methyl-phenyl)-9-methyl-9H-purin-6-yl]-amine 
• 672958-42-8 (2,6-difluoro-phenyl)-[2-(4-fluoro-phenyl)-9-methyl-9H-purin-6-yl]-amine 
• 672958-37-1 [2-(3-chloro-phenyl)-9-methyl-9H-purin-6-yl]-(2,6-difluoro-phenyl)-amine 
• 672958-43-9 (2,6-difluoro-phenyl)-[2-(3-fluoro-phenyl)-9-methyl-9H-purin-6-yl]-amine 
• 672958-38-2 [2-(2-chloro-phenyl)-9-methyl-9H-purin-6-yl]-(2,6-difluoro-phenyl)-amine 
• 672958-44-0 (2,6-difluoro-phenyl)-[2-(2-fluoro-phenyl)-9-methyl-9H-purin-6-yl]-amine 
• 672958-46-2 (2,6-difluoro-phenyl)-[2-(2,4-difluoro-phenyl)-9-methyl-9H-purin-6-yl]-amine 
• 672958-47-3 (2,6-difluoro-phenyl)-[2-(3,5-difluoro-phenyl)-9-methyl-9H-purin-6-yl]-amine 

Relevant articles and documents

Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists

Recognition of nucleosides at adenosine receptors (ARs) is supported by multiple X-ray structures, but the structure of an adenine complex is unknown. We examined the selectivity of predicted A1AR and A3AR adenine antagonists that incorporated known agonist affinity-enhancing N6 and C2 substituents. Adenines with A1AR-favoring N6-alkyl, cycloalkyl and arylalkyl substitutions combined with an A3AR-favoring 2-((5-chlorothiophen-2-yl)ethynyl) group were human (h) A3AR-selective, e.g. MRS7497 17 (～1000-fold over A1AR). In addition, binding selectivity over hA2AAR and hA2BAR and functional A3AR antagonism were demonstrated. 17 was subjected to computational docking and molecular dynamics simulation in a hA3AR homology model to predict interactions. The SAR of nucleoside AR agonists was not recapitulated in adenine AR antagonists, and modeling suggested an alternative, inverted binding mode with the key N2506.55 H-bonding to the adenine N3 and N9, instead of N6 and N7 as in adenosine agonists.

2-alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: Their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A2B receptor

Novel adenosine antagonists, 2-alkynyl-8-aryl-9-methyladenine derivatives, were synthesized as candidate hypoglycemic agents. These analogues were evaluated for inhibitory activity on N-ethylcarboxamidoadenosine (NECA)-induced glucose production in primar

Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors

Novel C-2, C-6, N-9 trisubstituted purines derived from the olomoucine/roscovitine lead structure were synthesized and evaluated for their ability to inhibit starfish oocyte CDK1/cyclin B, neuronal CDK5/p35 and erk1 kinases in purified extracts. Structure